Compare ACXP & NUTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ACXP | NUTX |
|---|---|---|
| Founded | 2017 | 2011 |
| Country | United States | United States |
| Employees | N/A | 944 |
| Industry | Biotechnology: Pharmaceutical Preparations | Retail: Computer Software & Peripheral Equipment |
| Sector | Health Care | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 8.3M | 912.4M |
| IPO Year | 2021 | 2009 |
| Metric | ACXP | NUTX |
|---|---|---|
| Price | $1.65 | $147.01 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 2 |
| Target Price | $95.50 | ★ $252.50 |
| AVG Volume (30 Days) | 84.5K | ★ 95.6K |
| Earning Date | 05-12-2026 | 04-30-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 7.93 |
| EPS | N/A | ★ 6.52 |
| Revenue | N/A | ★ $875,257,000.00 |
| Revenue This Year | N/A | $6.12 |
| Revenue Next Year | N/A | $4.04 |
| P/E Ratio | ★ N/A | $20.49 |
| Revenue Growth | N/A | ★ 82.36 |
| 52 Week Low | $0.29 | $77.21 |
| 52 Week High | $8.34 | $193.07 |
| Indicator | ACXP | NUTX |
|---|---|---|
| Relative Strength Index (RSI) | 34.10 | 64.85 |
| Support Level | $1.37 | $143.94 |
| Resistance Level | $2.26 | $161.67 |
| Average True Range (ATR) | 0.12 | 8.35 |
| MACD | -0.00 | 0.90 |
| Stochastic Oscillator | 13.43 | 100.00 |
Acurx Pharmaceuticals Inc is a late-stage biopharmaceutical company focused on developing a new class of small-molecule antibiotics for difficult-to-treat bacterial infections. Its approach is to develop antibiotic candidates with a Gram-positive selective spectrum (GPSS) that block the active site of the Gram-positive specific bacterial enzyme deoxyribonucleic acid (DNA) polymerase IIIC (pol IIIC), inhibiting DNA replication and Gram-positive bacterial cell death. Its research and development pipeline includes antibiotic product candidates targeting Gram-positive bacteria, including Clostridioides difficile, methicillin-resistant Staphylococcus aureus, vancomycin-resistant Enterococcus, and drug-resistant Streptococcus pneumoniae and B. anthracis. It operates in a single segment.
Nutex Health Inc is a physician-led, healthcare services and operations company with various hospital facilities in the U.S. states (hospital division), and a primary care-centric, risk-bearing population health management division. The company has three segments: the hospital division, the PHM division, and the real estate division. The hospital division implements and operates health care models, including micro-hospitals, specialty hospitals and hospital outpatient departments (HOPDs). The population health management (PHM) division owns and operates provider networks such as independent physician associations (IPAs). The Real Estate Entities own the land and hospital buildings which are leased to its hospital entities. The majority of the revenue is derived from the Hospital division.